Rafael Amado Sells 7,583 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Rafael Amado sold 7,583 shares of Zai Lab stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the sale, the insider now directly owns 33,834 shares in the company, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zai Lab Stock Up 2.0 %

NASDAQ ZLAB opened at $25.30 on Friday. The stock has a market cap of $2.77 billion, a P/E ratio of -9.13 and a beta of 1.00. Zai Lab Limited has a twelve month low of $13.48 and a twelve month high of $36.60. The company’s 50-day simple moving average is $27.98 and its 200 day simple moving average is $23.05.

Wall Street Analyst Weigh In

ZLAB has been the subject of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research report on Friday, October 25th. JPMorgan Chase & Co. raised their target price on Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research report on Monday, October 21st.

Institutional Investors Weigh In On Zai Lab

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Zai Lab by 26.4% during the 3rd quarter. Geode Capital Management LLC now owns 43,626 shares of the company’s stock worth $1,053,000 after buying an additional 9,107 shares during the period. M&T Bank Corp raised its stake in Zai Lab by 9.6% during the third quarter. M&T Bank Corp now owns 25,188 shares of the company’s stock worth $608,000 after acquiring an additional 2,209 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of Zai Lab during the third quarter valued at $369,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Zai Lab in the 3rd quarter valued at $225,000. Finally, XTX Topco Ltd grew its holdings in shares of Zai Lab by 8.0% in the 3rd quarter. XTX Topco Ltd now owns 31,618 shares of the company’s stock worth $763,000 after purchasing an additional 2,335 shares during the last quarter. 41.65% of the stock is currently owned by institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.